Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
J Med Food. 2011 Jul-Aug;14(7-8):718-23. doi: 10.1089/jmf.2010.1195. Epub 2011 Jun 1.
Uremic patients with diabetes suffer from high levels of oxidative stress due to regular hemodialysis therapy (neutrophil activation induced by hemo-incompatibility between the hemodialyser and blood) and complications associated with diabetes. Several plasma biomarkers were screened in 13 uremic diabetic patients after receiving the mixture of (-)-epigallocatechin gallate (EGCG), a major component of green tea extract, and Amla extract (AE), from Emblica officinalis, the Indian gooseberry, for 3 months. We found that oral administration of a 1:1 mixture of EGCG and AE for 3 months significantly improved antioxidant defense as well as diabetic and atherogenic indices in uremic patients with diabetes. Furthermore, no significant changes in hepatic function, renal function, or inflammatory responses were observed. These results suggest that a 1:1 combination of EGCG and AE is a safe and effective treatment for uremic patients with diabetes.
尿毒症糖尿病患者由于常规血液透析治疗（血液透析器与血液之间的血液不相容性引起的中性粒细胞活化）和与糖尿病相关的并发症而遭受高水平的氧化应激。在接受混合（-）-表没食子儿茶素没食子酸酯（EGCG）和印度醋栗（Emblica officinalis）提取物（AE）混合物 3 个月后，对 13 例尿毒症糖尿病患者进行了几种血浆生物标志物筛选。我们发现，口服 EGCG 和 AE 的 1:1 混合物 3 个月可显著改善尿毒症糖尿病患者的抗氧化防御以及糖尿病和动脉粥样硬化指标。此外，肝功能、肾功能或炎症反应均无明显变化。这些结果表明，EGCG 和 AE 的 1:1 组合是尿毒症糖尿病患者安全有效的治疗方法。
